We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+4.66%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.94B
AUM Growth
+$1.21B
Cap. Flow
+$1.03B
Cap. Flow %
14.89%
Top 10 Hldgs %
53.97%
Holding
274
New
81
Increased
95
Reduced
45
Closed
48

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$73.4M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72M
3
JNJ icon
Johnson & Johnson
JNJ
+$64.2M
4
CL icon
Colgate-Palmolive
CL
+$62.8M
5
XRAY icon
Dentsply Sirona
XRAY
+$52.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$73.1M
2
FRPT icon
Freshpet
FRPT
+$58.3M
3
PARA
Paramount Global Class B
PARA
+$48M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$43.7M
5
KYNB
Kyntra Bio
KYNB
+$32.8M

Sector Composition

Rank Sector Weight
1 Healthcare 43.57%
2 Consumer Staples 5.26%
3 Consumer Discretionary 4.88%
4 Technology 4.62%
5 Communication Services 2.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.74B 25.05%
4,250,000
+900,000
+27% +$359M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$874M 12.59%
4,900,000
+700,000
+17% +$129M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.7B
$161M 2.32%
1,592,000
+692,000
+77% +$72M
TVTX icon
4
Travere Therapeutics
TVTX
$5.33B
$161M 2.31%
7,148,000
+736,000
+11% +$15.6M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.68B
$158M 2.27%
4,350,000
-6,000
-0.1% -$231K
PTCT icon
6
PTC Therapeutics
PTCT
$6.37B
$142M 2.04%
2,924,000
-472,000
-14% -$21.6M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$137M 1.98%
3,692,000
+204,000
+6% +$9.18M
INCY icon
8
Incyte
INCY
$23.5B
$135M 1.95%
1,872,000
+460,000
+33% +$36M
BIIB icon
9
Biogen
BIIB
$29.9B
$125M 1.8%
450,000
+50,000
+13% +$13.8M
GSK icon
10
GSK
GSK
$103B
$115M 1.66%
3,236,000
+180,000
+6% +$6.3M
AMZN icon
11
Amazon
AMZN
$2.5T
$95.4M 1.37%
924,000
-240,000
-21% -$23.2M
EXAS
12
DELISTED
Exact Sciences
EXAS
$92M 1.32%
1,356,000
-180,000
-12% -$11.6M
UNH icon
13
UnitedHealth
UNH
$382B
$90.7M 1.31%
192,000
+152,000
+380% +$73.4M
XRAY icon
14
Dentsply Sirona
XRAY
$2.59B
$88.6M 1.28%
2,256,000
+1,420,000
+170% +$52.1M
ARGX icon
15
argenx
ARGX
$57.4B
$83.5M 1.2%
224,000
+54,000
+32% +$20M
GOOGL icon
16
Alphabet (Google) Class A
GOOGL
$3.91T
$83M 1.19%
800,000
-176,000
-18% -$16.9M
ENTA icon
17
Enanta Pharmaceuticals
ENTA
$372M
$81.4M 1.17%
2,012,000
-66,000
-3% -$3.15M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.16B
$79.5M 1.14%
3,460,000
+710,000
+26% +$18.9M
FRPT icon
19
Freshpet
FRPT
$2.83B
$78.6M 1.13%
1,187,000
-949,000
-44% -$58.3M
ALKS icon
20
Alkermes
ALKS
$8.82B
$76.8M 1.11%
2,724,000
-176,000
-6% -$4.8M
OGN icon
21
Organon & Co
OGN
$3.55B
$75.3M 1.08%
3,200,000
+800,000
+33% +$21.5M
CL icon
22
Colgate-Palmolive
CL
$72.6B
$71.1M 1.02%
946,000
+845,000
+837% +$62.8M
JNJ icon
23
Johnson & Johnson
JNJ
$635B
$71M 1.02%
457,883
+397,883
+663% +$64.2M
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$121B
$69.3M 1%
220,000
+72,000
+49% +$21.6M
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.6B
$66.9M 0.96%
276,000
+68,000
+33% +$18.5M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Armistice Capital held 274 positions worth $6.94B, up 21% from $5.73B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Armistice Capital deployed $1.03B of net new capital in Q1 2023, opening 81 new positions and adding to 95 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 1,376,000 shares worth $39.4M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 46% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Freshpet, an estimated $58.3M trimmed.

  • Armistice Capital's largest Q1 2023 buy was DICE Therapeutics, Inc. Common Stock: 1,376,000 shares worth $39.4M.
  • Armistice Capital added most to UnitedHealth in Q1 2023, an estimated $73.4M increase.
  • Armistice Capital's biggest Q1 2023 reduction was Freshpet, cutting an estimated $58.3M.
  • Armistice Capital fully exited Pacira BioSciences in Q1 2023, selling an estimated $73.1M.
  • Armistice Capital's ten largest holdings make up 54% of its $6.94B portfolio in Q1 2023.
  • Armistice Capital opened 81 new positions and closed 48 in Q1 2023.
  • Armistice Capital's portfolio value rose 21% quarter-over-quarter to $6.94B.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.